Atrial Fibrillation
Sunday, December 16th, 2012
American Journal of Cardiology: 12/15/12 Warfarin decreases risk of stroke for patients with atrial fibrillation (AF) dependent on percent time in the therapeutic range (TTR) with an international normalized ratio (INR) of 2 to 3. We hypothesized that gender differences in ischemic stroke risk are related to TTR. From the AFFIRM database of 4,060 patients with […]
Atrial Fibrillation
Friday, December 7th, 2012
Biomedcentral.com: 12/4/12 Atrial fibrillation (AF) is a common arrhythmia of substantial public health importance. Recent evidence demonstrates a heritable component underlying AF, and genetic discoveries have identified common variants associated with the arrhythmia. Ultimately one hopes that the consideration of genetic variation in clinical practice may enhance care and improve health outcomes. In this review we […]
Atrial Fibrillation
Saturday, December 1st, 2012
JACC: 12/4/12 Atrial fibrillation (AF) is associated with increased risk for stroke and systemic embolism. There is plausible evidence linking inflammation to the initiation and perpetuation of AF and AF-related thrombosis. Various inflammatory markers (C-reactive protein, tumor necrosis factor-α, interleukin-2, interleukin-6, and interleukin-8) have been associated with AF. Proposed mechanisms linking inflammation and the prothrombotic […]
Atrial Fibrillation
Saturday, December 1st, 2012
BMJ: 11/27/12 Objectives To examine the risk of atrial fibrillation in relation to the whole spectrum of thyroid function in a large cohort of patients. Design Population based cohort study of general practice patients identified by linkage of nationwide registries at the individual level. Setting Primary care patients in the city of Copenhagen. Subjects Registry data for 586 460 adults who […]
Atrial Fibrillation
Saturday, December 1st, 2012
JAMA: 11/26/12 Background It is unknown whether atrial fibrillation (AF) is associated with an increased risk of sudden cardiac death (SCD) in the general population. This association was examined in 2 population-based cohorts. Methods In the Atherosclerosis Risk in Communities (ARIC) Study, we analyzed data from 15 439 participants (baseline age, 45-64 years; 55.2% women; and […]
Atrial Fibrillation
Saturday, December 1st, 2012
AHA: 11/20/12 Predicting Response to Thrombolysis and Clinical Outcomes Background and Purpose—Atrial fibrillation (AF) increases the risk of stroke and is associated with poor stroke outcomes. Limited tools are available to evaluate clinical outcomes and response to thrombolysis in stroke patients with AF. Methods—We applied the iScore (http://www.sorcan.ca/iscore), a validated risk score, to consecutive patients […]
Atrial Fibrillation
Saturday, December 1st, 2012
AHA: 8/2/12 The rate of stroke among adults with atrial fibrillation (AF) varies widely, ranging between 1% and 20% annually (mean 4.5% per year) depending on comorbidities and a patient’s history of prior cerebrovascular events.1 Stratification of stroke risk is important, because the major risk of antithrombotic medications used to lower the incidence of AF-related stroke […]
Atrial Fibrillation
Thursday, November 22nd, 2012
AMA: 11/19/12 Background—Ethnic differences in cardiac arrhythmia incidence have been reported, with a particularly high incidence of sudden cardiac death (SCD) and low incidence of atrial fibrillation in individuals of African ancestry. We tested the hypotheses that African ancestry and common genetic variants are associated with prolonged duration of cardiac repolarization, a central pathophysiological determinant of […]
Atrial Fibrillation
Thursday, November 22nd, 2012
Sciencedirect: 11/10 Statistical modeling of atrioventricular (AV) nodal function during atrial fibrillation (AF) is revisited for the purpose of defining model properties and improving parameter estimation. The characterization of AV nodal pathways is made more detailed and the number of pathways is now determined by the Bayesian information criterion, rather than just producing a probability as […]
Atrial Fibrillation
Thursday, November 22nd, 2012
AHA: 8/21/12 Background—Oral anticoagulants such as apixaban, dabigatran, and rivaroxaban are alternatives to warfarin for preventing events in patients with atrial fibrillation. Direct comparative studies between agents are unavailable. Our objective was to conduct an adjusted indirect comparison meta-analysis between new oral agents in atrial fibrillation. Methods and Results—We searched MEDLINE and Cochrane Central through […]
